Aastrom Biosciences has treated first patients in ixCELL-DCM Phase 2b trial of ixmyelocel-T in patients with advanced heart failure due to ischemic dilated cardiomyopathy (ischemic DCM). The trial is designed to assess the safety and ...
Tags: Aastrom, Ixcell-Dcm Phase 2B Trial